Explore the full ADLM 2025 Scientific Program Online
Browse by day, topic, type, and more to discover the latest in lab medicine in ADLM 2025 Plenaries, Scientific Sessions, Roundtables, University Courses, and special events.
2025 Contestants
Learn about the 2025 contestants and their disruptive technologies. Finalists will be announced in late May.
Semifinalists
BloodScan Biotech Inc. | Labyrinth One
C2N Diagnostics | PrecivityAD2™
Rarity Bioscience | Rarity superRCA®
BloodScan Biotech Inc.
Product/Technology
Labyrinth One
Organization description
BloodScan Biotech Inc. is a biotechnology company pioneering next-generation liquid biopsy solutions to advance precision oncology. Spun out from the University of Michigan in 2023, BloodScan focuses on improving circulating tumor cell (CTC) isolation technology to enhance early cancer detection, real-time treatment monitoring, and personalized therapy selection.
The company’s core technology, the Labyrinth One – Automated CTC Enrichment System, enables high-throughput, label-free isolation of viable CTCs from blood samples. Unlike conventional antibody-based capture methods, Labyrinth One delivers superior purity and efficiency, making CTC analysis feasible for routine laboratory diagnostics. By providing rapid, high-purity CTC enrichment in just 15 minutes, Labyrinth One integrates seamlessly into existing laboratory workflows, supporting both research and clinical applications in cancer diagnostics.
BloodScan Biotech’s mission is to bridge the gap between academic innovation and clinical application, ensuring that cutting-edge liquid biopsy technologies reach laboratory medicine and patient care. Through strategic collaborations with research institutions, clinical laboratories, and oncology centers, BloodScan is working to accelerate the adoption of CTC-based diagnostics, ultimately improving cancer detection and treatment outcomes.
Product/Technology summary
Labyrinth One is a next-generation circulating tumor cell (CTC) enrichment system that enables high-purity, label-free isolation of viable CTCs in just 15 minutes. Built on BloodScan Biotech’s patented Labyrinth microfluidic technology, Labyrinth One overcomes the limitations of existing CTC isolation methods, which suffer from low recovery rates, high contamination, and labor-intensive workflows. Unlike EpCAM-based systems that miss mesenchymal CTCs or size-based filtration methods with inconsistent purity, Labyrinth One captures all CTC phenotypes with >95% recovery and 5-log depletion of background blood cells, ensuring unbiased analysis for both research and clinical applications.
By combining automation, affordability, and clinical scalability, Labyrinth One is poised to disrupt the liquid biopsy market and accelerate CTC-based diagnostics into mainstream oncology practice. The global liquid biopsy market, projected to exceed $10 billion by 2030, presents an immense opportunity for Labyrinth One to become the gold standard for CTC enrichment in research, pharmaceutical drug development, and routine cancer diagnostics.
BloodScan Biotech has developed a scalable commercialization strategy, beginning with early adoption in research institutions and pharmaceutical collaborations before expanding into clinical diagnostics through regulatory-driven approvals and reimbursement integration. With a $50,000 price point—50-80% lower than competing systems—and a pay-per-test consumables model, Labyrinth One offers a cost-effective and accessible solution for laboratories worldwide.
By addressing critical barriers in CTC isolation, BloodScan Biotech is not just launching a product—we are transforming CTC-based diagnostics into a global standard in precision oncology.
C2N Diagnostics
Product/Technology
PrecivityAD2™
Organization description
C2N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced blood-based biomarker diagnostic tests in the field of brain health. Currently, C2N’s transformative product is the PrecivityAD2™ blood test that identifies brain amyloid pathology; a hallmark for Alzheimer’s disease (AD).
C2N scientists have developed and validated high-resolution mass spectrometry-based biomarkers for quantifying plasma amyloid-β42 (Aβ42), Aβ40, phospho-tau217, non-phospho-tau217, and ApoE proteotyping. These biomarker measures are used in an algorithm that was derived by comparing the biomarker measures to the ‘gold standard’ brain amyloid PET imaging. The algorithm generates the Amyloid Probability Score 2 (APS2): a clinically useful indication for the likelihood that a patient has brain amyloid pathology1,2. C2N’s Laboratory is CLIA-certified, CAP-accredited and operates under ISO 13485 quality standards. C2N biomarker services are used for: clinical decision-making to improve patient care3, including AD diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration4–6; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health.
C2N blood tests have been used in over 200 AD and other research studies throughout the US and the world, including landmark treatment and prevention trials involving disease-modifying therapies that are changing the trajectory of AD5,6. Over 50,000 PrecivityAD™-related biomarker measures have been reported in peer-reviewed publications, with many manuscripts currently under review.
Product/Technology summary
The PrecivityAD2™ blood test is transforming how physicians, healthcare providers, clinical trialists and researchers identify the presence or absence of brain amyloid pathology in people with cognitive impairment. The PrecivityAD2™ blood test and APS2 value provide an aid to the diagnosis of AD previously accomplished using cerebrospinal fluid (CSF) biomarker analysis or brain amyloid PET imaging. The PrecivityAD2™ blood test is simpler, less burdensome, less expensive for patients and clinicians than CSF sampling or brain amyloid imaging, but equally as accurate as CSF testing.
C2N scientists pioneered the high throughput automated sample preparation workflow, developed and validated the liquid chromatography-tandem mass spectrometry analytical platform (LC-MS/MS) for the quantification of very low abundant plasma proteins/peptides (Aβ42, Aβ40, phosphorylated- and non-phosphorylated-tau217 peptides (pg/mL)), and validated the algorithmic Amyloid Probability Score 2 (APS2). After quantifying these plasma biomarkers and using a single prespecified APS2 cut point in 300 patients being seen by dementia specialists, the APS2 had a diagnostic accuracy of 91% (95% CI 88-94%), positive predictive value = 91% (95% CI 87-95%), and negative predictive value = 91% (95% CI 87-95%) when compared to brain amyloid pathology. PrecivityAD2 test’s diagnostic performance represents an outstanding improvement over routine patient exams with cognitive testing and a CT scan, where the clinical misdiagnosis rate (without blood biomarkers) is 25-30%.
Chemeleon
Product/Technology
BINDS-AMI Assay
Organization description
Chemeleon is a diagnostics company revolutionizing acute and emergency care with instrument-free, lab-precision testing at the point of need. Our proprietary Binding-Induced Nanostructured Dynamic Surface (BINDS) Assay enables rapid, high-sensitivity biomarker detection, delivering results in under two minutes without requiring complex instrumentation or specialized personnel. This innovation makes gold-standard diagnostics accessible in hospitals, ambulances, and resource-limited settings where rapid decision-making is critical.
Our connection to laboratory medicine lies in bridging the gap between centralized lab testing and point-of-care diagnostics. Traditional lab-based tests for conditions like Acute Myocardial Infarction (AMI) can take over an hour, delaying life-saving interventions. Chemeleon’s technology combines high accuracy, rapid turnaround, and ease of use, allowing clinicians to make immediate, informed decisions that improve patient outcomes and reduce emergency department congestion.
Chemeleon operates independently, collaborating with leading medical institutions, researchers, and healthcare providers to drive innovation in acute and emergency diagnostics. Our technology is wholly owned and protected by a strong intellectual property portfolio, with no subsidiaries or out-licensing agreements.
By eliminating reliance on expensive lab infrastructure, Chemeleon’s BINDS Assay has the potential to reshape laboratory medicine, making high-performance diagnostics available anytime, anywhere—from the bedside and EMS to urgent care and global health settings.
Product/Technology summary
Chemeleon’s BINDS Assay (Binding-Induced Nanostructured Dynamic Surface) is a first-of-its-kind, instrument-free diagnostic platform that delivers lab-precision results in under two minutes. Our lead product targets Acute Myocardial Infarction (AMI) by detecting and quantifying cardiac troponins with 99.2% sensitivity and 90.5% specificity—without requiring costly lab equipment or trained personnel.
Current AMI diagnostics rely on centralized lab tests that take over an hour or point-of-care devices that require expensive instrumentation. These delays contribute to 240,000 unnecessary deaths annually in the U.S. alone. Chemeleon’s low-cost, ultra-rapid solution enables emergency departments, EMS teams, and urgent care providers to diagnose AMI immediately, reducing ED overcrowding, accelerating treatment, and improving patient outcomes.
Our disruptive technology leverages proprietary nanoengineered surfaces that convert biomarker binding into a visible color change, eliminating the need for electronic readers. This makes our platform highly scalable, deployable anywhere, and accessible in both high-tech and resource-limited settings.
Chemeleon’s BINDS Assay represents a paradigm shift in acute care diagnostics, bringing the speed of lateral flow assays together with the precision of lab-based testing. By reducing diagnostic bottlenecks and improving time-to-treatment, our platform has the potential to redefine the standard of care for AMI and beyond.
MagIC Lifescience
Product/Technology
MagChipR™
Organization description
MagIC Lifescience, a Stanford University spinout founded in 2021, is dedicated to expanding access to high-performance molecular diagnostics through its patented giant magnetoresistive (GMR)-based detection technology and proprietary ultra-fast polymerase chain reaction (PCR) chemistry. The MagChipR™ Platform provides molecular diagnostic results in under 20 minutes enabling same-visit, susceptibility-guided treatment, improving diagnostic and treatment efficiency, reducing costs, and improving patient outcomes.
Our mission is to make highly multiplexed molecular testing viable at the point of care (POC). Faster, more accessible testing reduces antimicrobial resistance (AMR), improves patient care, and strengthens global health.
A World-Class Team with Proven Expertise
MagIC Lifescience’s XPRIZE-winning team combines expertise across:
- Biosensor innovation & GMR technology – Stanford pioneers in nanoscale detection and biosensor engineering.
- Ultra-fast PCR & molecular assay development – Specialists in high-sensitivity, multiplexed amplification.
- Regulatory & CLIA waiver strategy – Experts with a track record of securing FDA clearance and global compliance.
- Commercialization & market adoption – Leaders who successfully launched and scaled BioFire Diagnostic’s FilmArray.
MagIC Lifescience is guided by top clinical and industry experts, including::
- Regulatory and CLIA waiver specialists advising to streamline FDA clearance.
- Key opinion leaders (KOLs) in infectious disease, sexually transmitted infections (STI), and antimicrobial susceptibility diagnostics, including CDC and WHO guidelines contributors.
- Strategic partnerships with clinical study sites, ensuring rapid validation and access to diverse patient specimens.
With cutting-edge technology, world-class expertise, and industry-leading advisors, MagIC Lifescience is poised to redefine infectious disease testing in the POC as a global reality.
Product/Technology summary
MagIC Lifescience is transforming POC molecular diagnostic testing with the MagChipR Platform, the first affordable, ultra-fast PCR system with high multiplexing capability. Delivering lab-quality pathogen and antimicrobial susceptibility results in under 20 minutes. MagChipR enables same-visit diagnosis and treatment, advancing the ‘Test and Treat’ model to improve patient outcomes while reducing costly delays.
Unlike existing POC molecular platforms with high test costs, limited multiplexing, and slow time-to-results, MagChipR is the first cost-effective and highly multiplexed PCR solution designed for real-world clinical adoption [Supplemental page 9]. By reducing test costs to $40 per cartridge, aligning with $70.20 CPT reimbursement, MagChipR makes high-performance POC molecular testing a financially and operationally viable solution for clinics.
MagChipR’s first commercial application targets the rising epidemic of STIs, offering a single-test panel for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG). If NG or MG are detected, the platform performs antimicrobial susceptibility testing using high-resolution melt analysis. This ensures patients receive the proper treatment immediately, reducing unnecessary antibiotic use, missed follow-ups, and AMR.
Powered by Stanford-developed GMR biosensor technology by the co-founders, MagChipR eliminates the inefficiencies of fluorescence-based detection, lowering costs, accelerating time-to-results, and expanding multiplexing capacity—overcoming key adoption barriers faced by other CLIA waived platforms.
With a scalable business model, global market potential, and first-mover advantage, MagChipR is set to disrupt the $10B STI diagnostics market and expand into the broader $21.4B infectious disease market—bringing high-performance molecular diagnostics to the point of care worldwide.
Rarity Bioscience
Product/Technology
Rarity superRCA®
Organization description
Rarity Bioscience, founded in 2021, is a spin-out company from Uppsala University with a purpose to democratize mutation detection and improve clinical decisions through fast, sensitive, and reliable mutation detection technology.The company was established to commercialize the superRCA assay technology, which was discovered, patented and developed by Dr. Lei Chen, a PhD in molecular biology, while working in Professor Ulf Landegren's team at the Department of Immunology, Genetics and Pathology.
The superRCA (super Rolling Circle Amplification) technology is an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in liquid biopsy or tissue samples. It can detect 1 mutation out of 100,000 wild-type DNA molecules, offering remarkable sensitivity for identifying cancer mutations and monitoring disease progression.
Key features of the superRCA technology include:
- Ultra-high sensitivity for detecting single or multiple mutation targets
- Ability to analyze genomic and cell-free DNA in liquid biopsies
- Use of standard flow cytometers for sample analysis, making it accessible to many labs and CROs
- Potential for early detection of disease recurrence and monitoring treatment response
Rarity Bioscience's innovative approach has the potential to enhance precision medicine by enabling more accurate and timely detection of rare mutations, particularly in cancer research and care. The company's first product was launched in spring 2022, and they continue to expand their library of assays to provide more options for users.
Product/Technology summary
Rarity Bioscience has developed superRCA®, an ultra-sensitive molecular amplification technology originating from research at Uppsala University. This innovative platform converts nucleic acid sequences into fluorescent particles, enabling molecular analysis via standard flow cytometry—a widely available instrument in hematology and pathology labs. By leveraging existing infrastructure, superRCA® allows seamless adoption of advanced molecular diagnostics without additional capital investment.
SuperRCA® achieves exceptional sensitivity, detecting one mutation among 100,000 wild-type DNA molecules. This is accomplished through two consecutive Rolling Circle Amplification (RCA) reactions, significantly enhancing specificity and precision. 10–100 times more sensitive than gold-standard methods like digital PCR (dPCR) and Next-Generation Sequencing (NGS), superRCA® is ideally suited for liquid biopsy and cancer monitoring, where detecting ultra-low levels of disease is critical. A library covering 300+ mutations has been applied across multiple cancers, including hematologic and solid tumors.
One of superRCA®’s most impactful applications is in Minimal/Measurable Residual Disease (MRD) detection. By identifying residual cancer DNA in peripheral blood with unmatched sensitivity, it enables earlier relapse detection, leading to better patient outcomes. Frequent monitoring with superRCA® empowers clinicians to detect and address relapses at the earliest stages, facilitating timely, potentially life-saving interventions.
By combining unparalleled sensitivity, cost-effectiveness, and compatibility with existing workflows, superRCA® is transforming molecular diagnostics and making ultra-sensitive cancer monitoring more accessible than ever.
Truvian
Product/Technology
TruAnalyzer
Organization description
Truvian is a pioneering healthcare company with a team of innovative scientists and problem solvers dedicated to revolutionizing blood testing through innovation and novel workflows.
Our mission is to provide accessible, lab-accurate blood tests that empower clinicians and patients to make informed, timely medical decisions. By leveraging bleeding-edge technologies, Truvian simplifies and automates the current blood testing workflow, reducing time and cost while enhancing quality of care. Over the past few years, we have been deeply focused on developing our first-in-class blood testing platform and validating its performance to deliver central laboratory-quality results.
Our compact, easy-to-use solution is designed for point-of-care settings, making routine blood tests possible in clinics, pharmacies, and even rural health centers. The Truvian platform is purpose-built to provide results within minutes and meters from blood draw, while also eliminating logistical costs and risks to sample quality associated with shipping samples over long distances to centralized labs.
A critical gap in healthcare today is the ability to serve what are called “healthcare deserts”—areas lacking access to quality care, at times even basic care. Truvian’s platform enables clinicians to deliver the same quality of care at scale to every part of the country. This capability isn’t just about convenience—it’s about equity. With Truvian’s solution, clinicians can extend their reach into medical deserts, creating “healthcare oases” for those who need them most.
The result? Improved access, timely interventions, and healthier communities.
Product/Technology summary
Nearly 50% of the US population skips their doctor-ordered laboratory tests, often deterred by the number of blood tubes drawn and long wait times for results. As a result, approximately 60% of US adults live with at least one chronic health issue.
About 9 years ago, a band of scientists and engineers set on a journey to change this broken and antiquated world of blood testing. And thus, Truvian was born—to answer a simple question: How do we make routine blood testing simple and convenient for anyone, anywhere?
We’ve now created the world’s first proven multi-modal platform, capable of simultaneously performing clinical chemistry, immunoassay, and hematology tests with <10 drops of whole blood. Our onsite solution provides comprehensive, lab-accurate results, ensuring patients receive actionable insights within a single visit. Independently validated by an academic institution and multiple external studies, our platform delivers central laboratory-quality results in any setting. Backed by rigorous scientific validation and industry expertise, every test inspires confidence.
The Truvian solution empowers patients to take control of their health. Patients can track how lifestyle changes impact their blood results over time (longitudinal record), while clinicians can provide differentiated patient experience and unlock a new revenue stream. Payers benefit from streamlined workflows, better patient outcomes, and reduced costs.
Truvian envisions a future where blood testing is available at every pharmacy and clinic. We are creating a more sustainable healthcare ecosystem, delivering timely, accurate insights to patients when and where they need them.